Efficacy and Safety of Canakinumab in sJIA Patients with and without Fever at Baseline: Results from an Open‐label, Active Treatment Extension Study

Objective To evaluate the long‐term efficacy, safety of canakinumab and explore prediction of response in systemic juvenile idiopathic arthritis (sJIA) patients with and without fever at treatment i…

Read the full article here

Related Articles